I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes mellitus (DM), a growing health problem globally, has reached epidemic proportions in India. Recently, Fas-mediated apoptosis has been proposed as a causative factor responsible for neuronal degeneration in diabetic polyneuropathy (DPN), but there are few studies to show association of serum soluble Fas ligand (sFasL) level with severity of neuropathy.

A[IMS AND]{.smallcaps} O[BJECTIVE]{.smallcaps} {#sec1-2}
==============================================

The aim of this study was to investigate whether serum sFasL, a transmembrane glycoprotein involved in apoptosis, has any association with severity of peripheral neuropathy in Type 2 DM. If positively associated with serum sFas level, it can definitely suggest a role for apoptotic dysregulation in pathophysiology of DPN. Thus, targeting and inhibiting Fas receptor offer an option for DPN therapy.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-3}
=================================================

The study was conducted in Department of Physiology in collaboration with Department of Endocrinology, IPGME&R. Subjects were randomly chosen and meticulous screening was done as per criteria to select cases. sFasL levels in serum were assessed using ELISA method in three groups:

Group I: Healthy individuals (*n* = 16)Group II: Newly diagnosed diabetic controls (*n* = 16) without any complicationsGroup III: DPN cases (*n* = 33) with predominant neuropathy only.

All subjects underwent both neuroelectrophysiological procedures using "RMS nerve conduction velocity (NCV) EMG EP MARK II" and vibration perception threshold (VPT) using "Vibrometer VPT" for quantitative assessment of the severity of neuropathy. Using standard nerve conduction techniques, amplitudes, velocities, and latencies of both sensory and motor nerves were recorded.

The results were expressed as mean ± SD. *P* \< 0.05 was considered significant. Statistical analysis was done using the software GRAPHPAD PRISM Version 5.00 and Statistica Version 7.

R[EVIEW OF]{.smallcaps} L[ITERATURE]{.smallcaps} {#sec1-4}
================================================

Recent evidences suggest that there is increased level of sFas in serum of diabetic patients with neuropathy\[[@ref1]\] and that Fas-mediated apoptosis of neuronal cell line is likely to be responsible for neuronal degeneration in DPN as this neuropathy can be blocked by anti-Fas antibody (ZB4).\[[@ref2]\] But till date, there is no study which shows correlation of serum sFas level with severity of DPN in Type 2 DM.

Hence, in the view increase incidence of DPN and possible role of Fas-mediated apoptosis in the etiopathogenesis of diabetic neuropathy,\[[@ref1][@ref2]\] we think it is quite rationale to presume that there may exist a correlation between severity of neuropathy and serum sFas level in patients of DPN in Type 2 DM.

R[ESULT AND]{.smallcaps} D[ISCUSSION]{.smallcaps} {#sec1-5}
=================================================

In this study, there is significant alteration in sFasL concentration among three groups \[[Figure 1](#F1){ref-type="fig"} and [Table 1a](#T1){ref-type="table"}\]. In Group I, the sFasL level is within normal range, i.e., \>0.1 ng/ml (mean = 225.30 ± 2.97). In Group II, sFasL concentration is significantly lower than healthy individual (Group I) (mean 161 ± 3.63) *P* \< 0.0001, but the value is within normal range. Thus, in both Groups I and II, sFasL concentration is within normal range which has been corroborated in several other studies.\[[@ref1][@ref2]\] But in contrary to most of the studies who reported normal sFasL levels in DPN,\[[@ref1][@ref2]\] we found highly significant decrease in sFasL level in patients with DPN, the mean being 87.53 ± 3.49 and intergroup statistical significance being \<0.0001 when compared with both healthy and diabetic controls. Two studies have reported that\[[@ref3][@ref4]\] decrease sFasL level in diabetic patient than healthy control and have related insulin resistance as a causal effect of decrease sFasL. This may be a common factor lowering sFasL concentration in our study. But a significant lowering of sFasL in patients with predominant neuropathy (Group III) cannot be explained only with insulin resistance. Tanaka *et al*.,\[[@ref5]\] in 1998 in his study, reported that cleavage of membrane bound FasL (mFasL) at conserved cleavage site to generate sFasL is a mechanism to prevent apoptosis. Hence, decrease sFasL concentration in DPN may be due to increased interaction between upregulated sFas with over expressed mFas and a lesser cleavage to enhance the apoptotic activity in DPN.

![Comparison of soluble Fas ligand (sFasL) level among three groups](IJEM-16-465-g001){#F1}

###### 

Comparison of serum soluble Fas ligand (sFasL) conc. with electrodiagnostic finding among three groups

![](IJEM-16-465-g002)

Concentration of sFasL when compared with NCV finding in each group \[Table [1a](#T1){ref-type="table"} and [b](#T2){ref-type="table"}\] revealed that NCV of median (sensory), sural, and peroneal (motor) was normal in Groups I and II (normal values: Median nerve: NCV = 56.2 ± 5.8 m/s, Amp = 38.5 ± 15.6 μV; sural nerve: NCV = 51.1 ± 5.9 m/s, Amp = 17.2 ± 6.7 μV; peroneal nerve: NCV = 48.3 ± 3.9 m/s, Amp = 5.1 ± 2.3 mV) without intergroup statistical significance. But there is gross decrease in both conduction velocity and amplitude in Group III subjects showing severe sensory (sural being absent in \>90% cases) and moderate motor neuropathy both inducing demyelination and axonopathy. This severe neuropathy corroborates with decrease sFasL concentration as shown in Table [1a](#T1){ref-type="table"} and [b](#T2){ref-type="table"}. This finding is in contrary to most of the studies where sFasL concentration remains normal in spite of altered electrodiagnostic finding.\[[@ref1][@ref2]\]

###### 

Intergroup statistical significance of nerve conduction velocity (NCV) and Concentration of serum soluble Fas ligand (sFasL)

![](IJEM-16-465-g003)

This observation, i.e., decreased sFasL has a direct correlation with severe neuropathy and is further substantiated when we compare sFasL concentration with severity of neuropathy graded according to VPT \[[Figure 2](#F2){ref-type="fig"}\]. Neuropathy has been graded according to VPT as mild, moderate, and severe (mild: VPT, 20-35; moderate: VPT, 36-50; severe: VPT, \>50) and it is observed that there is progressive decrease in the concentration of sFasL in these three groups of DPN. The intergroup comparison of sFasL concentration was statistically significant (*P* \< 0.0001). Point biserial correlation coefficient for the association between sFasL level and severity of DPN is negatively correlated \[*r*~PB~ = -0.73 (*P* \< 0.001)\]. Moreover, point biserial correlation coefficient of sFasL concentration and presence of moderate to severe VPT is also negatively correlated \[*r*~PB~ = --0.78 (*P* \< 0.001)\], showing that the severity of neuropathy is strongly associated with lowering of sFasL concentration. This is a novel finding and to our knowledge till date no study has compared sFasL concentration with the severity of neuropathy.

![Alteration of soluble Fas ligand (sFasL) concentration with the severity of nerve conduction velocity (DPN) graded according to VPT \[Intergroup comparison of sFasL conc. is statistically significant *P* \< 0.001\]](IJEM-16-465-g004){#F2}

Thus, we may conclude by saying that sFasL concentration decreases significantly with severity of neuropathy in Type 2 DM and may be considered a serum marker to assess the severity of DPN. But to fully establish the efficacy of this study, a larger sample size and longer follow-up are essential.
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